Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MAZ51 是一种 VEGFR-3酪氨酸激酶的选择性抑制剂。它抑制 VEGF-C 诱导的 VEGFR-3 激活,而没有阻断 VEGF-C 介导的 VEGFR2 刺激。它阻止增殖并诱导多种肿瘤细胞凋亡,具有抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 319 | 现货 | ||
2 mg | ¥ 466 | 现货 | ||
5 mg | ¥ 786 | 现货 | ||
10 mg | ¥ 1,220 | 现货 | ||
25 mg | ¥ 2,480 | 现货 | ||
50 mg | ¥ 3,690 | 现货 | ||
100 mg | ¥ 5,320 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 848 | 现货 |
产品描述 | MAZ51 is a VEGFR-3 (Flt-4) tyrosine kinase inhibitor. |
体外活性 | MAZ51 is able to block the proliferation of VEGFR-3-expressing human endothelial cells and is less potently able to induce their apoptosis.?MAZ51 also inhibits the proliferation and induces the apoptosis of a variety of non-VEGFR-3-expressing tumor cell lines[1]. |
体内活性 | In vivo, MAZ51 significantly inhibits the growth of rat mammary carcinomas.?These data establish MAZ51 as a compound with antitumor properties that inhibits tumor growth directly and also indirectly by interfering with tumor-host interactions[1]. |
分子量 | 314.38 |
分子式 | C21H18N2O |
CAS No. | 163655-37-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.33 mg/mL(10.59 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1809 mL | 15.9043 mL | 31.8086 mL | 79.5216 mL |
5 mM | 0.6362 mL | 3.1809 mL | 6.3617 mL | 15.9043 mL | |
10 mM | 0.3181 mL | 1.5904 mL | 3.1809 mL | 7.9522 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MAZ51 163655-37-6 Angiogenesis Apoptosis Tyrosine Kinase/Adaptors VEGFR EGFR growth phosphorylation Inhibitor inhibit PDGFRβ MAZ 51 tumor VEGF-D indolinone MAZ-51 IGF-1R VEGF-C Vascular endothelial growth factor receptor ligand-induced proliferation inhibitor